Reported Earnings • Apr 23
Full year 2025 earnings released: CN¥0.18 loss per share (vs CN¥0.18 loss in FY 2024) Full year 2025 results: CN¥0.18 loss per share (further deteriorated from CN¥0.18 loss in FY 2024). Revenue: CN¥1.17b (up 2.3% from FY 2024). Net loss: CN¥379.8m (loss widened 1.7% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Announcement • Apr 23
Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 20, 2026 Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: The Company's Meeting Room, Changsha, Hunan China Announcement • Mar 31
Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q1, 2026 Results on Apr 24, 2026 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report Q1, 2026 results on Apr 24, 2026 Buy Or Sell Opportunity • Mar 24
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 4.0% to CN¥3.67. The fair value is estimated to be CN¥2.93, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 21% over the last 3 years. Earnings per share has declined by 16%. New Risk • Jan 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). Buy Or Sell Opportunity • Jan 05
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 5.3% to CN¥3.56. The fair value is estimated to be CN¥2.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 21% over the last 3 years. Earnings per share has declined by 16%. Announcement • Dec 31
Hunan Er-Kang Pharmaceutical Co., Ltd to Report Fiscal Year 2025 Results on Apr 23, 2026 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report fiscal year 2025 results on Apr 23, 2026 Buy Or Sell Opportunity • Dec 17
Now 21% overvalued Over the last 90 days, the stock has fallen 6.7% to CN¥3.47. The fair value is estimated to be CN¥2.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 21% over the last 3 years. Earnings per share has declined by 16%. Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. GM & Non-Independent Director Qingrong Sun was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Buy Or Sell Opportunity • Oct 31
Now 26% overvalued Over the last 90 days, the stock has fallen 15% to CN¥3.61. The fair value is estimated to be CN¥2.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 21% over the last 3 years. Earnings per share has declined by 16%. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.001 (vs CN¥0.015 loss in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.001 (up from CN¥0.015 loss in 3Q 2024). Revenue: CN¥324.5m (up 39% from 3Q 2024). Net income: CN¥1.94m (up CN¥33.7m from 3Q 2024). Profit margin: 0.6% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Sep 30
Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q3, 2025 Results on Oct 30, 2025 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 28
Second quarter 2025 earnings released: EPS: CN¥0.005 (vs CN¥0.002 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.005 (up from CN¥0.002 in 2Q 2024). Revenue: CN¥328.3m (down 5.0% from 2Q 2024). Net income: CN¥9.52m (up 180% from 2Q 2024). Profit margin: 2.9% (up from 1.0% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Jul 02
Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2025 Results on Aug 28, 2025 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • Apr 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.3% average weekly change). Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.014 (vs CN¥0.001 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.014 (up from CN¥0.001 in 1Q 2024). Revenue: CN¥353.5m (up 28% from 1Q 2024). Net income: CN¥28.1m (up CN¥25.2m from 1Q 2024). Profit margin: 8.0% (up from 1.1% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Apr 23
Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2025 Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Changsha, Hunan China Announcement • Mar 31
Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q1, 2025 Results on Apr 23, 2025 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report Q1, 2025 results on Apr 23, 2025 Announcement • Dec 31
Hunan Er-Kang Pharmaceutical Co., Ltd to Report Fiscal Year 2024 Results on Apr 23, 2025 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report fiscal year 2024 results on Apr 23, 2025 Reported Earnings • Oct 25
Third quarter 2024 earnings released: CN¥0.015 loss per share (vs CN¥0.006 loss in 3Q 2023) Third quarter 2024 results: CN¥0.015 loss per share (further deteriorated from CN¥0.006 loss in 3Q 2023). Revenue: CN¥232.9m (down 41% from 3Q 2023). Net loss: CN¥31.8m (loss widened 168% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. New Risk • Sep 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 33% per year over the past 5 years. Announcement • Sep 30
Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report Q3, 2024 results on Oct 25, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.013 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.002 (down from CN¥0.013 in 2Q 2023). Revenue: CN¥345.6m (down 31% from 2Q 2023). Net income: CN¥3.40m (down 87% from 2Q 2023). Profit margin: 1.0% (down from 5.1% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. New Risk • Aug 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). Announcement • Jun 29
Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report first half, 2024 results on Aug 29, 2024 Announcement • Apr 26
Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024 Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Changsha, Hunan China Reported Earnings • Apr 25
Full year 2023 earnings released: CN¥0.095 loss per share (vs CN¥0.022 profit in FY 2022) Full year 2023 results: CN¥0.095 loss per share (down from CN¥0.022 profit in FY 2022). Revenue: CN¥1.78b (down 4.7% from FY 2022). Net loss: CN¥195.3m (down CN¥241.1m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 15% per year. Announcement • Mar 30
Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report Q1, 2024 results on Apr 27, 2024 Announcement • Dec 30
Hunan Er-Kang Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report fiscal year 2023 results on Apr 25, 2024 Reported Earnings • Oct 23
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: CN¥395.2m (down 12% from 3Q 2022). Net loss: CN¥11.9m (down 291% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 28
Second quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.004 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.013 (up from CN¥0.004 in 2Q 2022). Revenue: CN¥503.2m (up 13% from 2Q 2022). Net income: CN¥25.9m (up 242% from 2Q 2022). Profit margin: 5.1% (up from 1.7% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Announcement • Jun 03
Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023 Hunan Er-Kang Pharmaceutical Co. Ltd. announced 2022 final profit distribution plan to be implemented (A shares). Cash dividend/10 shares CNY 0.30000000 (tax included). Record date is 08 June 2023, Ex-date is 09 June 2023, Payment date is 09 June 2023. Announcement • May 20
Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan Hunan Er-Kang Pharmaceutical Co., Ltd, at its Annual General Meeting of 2022 held on 18 May 2023, approved 2022 profit distribution plan. The detailed profit distribution plan are as follows: Cash dividend/10 shares (tax included) of CNY 0.30000000. Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.011 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.013 (up from CN¥0.011 in 1Q 2022). Revenue: CN¥546.9m (up 28% from 1Q 2022). Net income: CN¥26.1m (up 16% from 1Q 2022). Profit margin: 4.8% (down from 5.3% in 1Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance. Announcement • Nov 16
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes Hunan Er-Kang Pharmaceutical Co. Ltd. at its EGM held on 14 November 2022 appointed Sun Qingrong as non-independent directors. Tan Xue appointed as independent directors. Li Haiyi appointed as non-employee supervisors. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. Deputy GM & Non Independent Director Xiangyang Shi was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.026 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.003 (down from CN¥0.026 in 3Q 2021). Revenue: CN¥446.8m (down 40% from 3Q 2021). Net income: CN¥6.22m (down 88% from 3Q 2021). Profit margin: 1.4% (down from 7.1% in 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 31
Second quarter 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.024 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.004 (down from CN¥0.024 in 2Q 2021). Revenue: CN¥444.2m (down 1.0% from 2Q 2021). Net income: CN¥7.55m (down 85% from 2Q 2021). Profit margin: 1.7% (down from 11% in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 28
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: CN¥0.38 loss per share (down from CN¥0.098 profit in FY 2020). Revenue: CN¥2.24b (down 6.2% from FY 2020). Net loss: CN¥791.2m (down 491% from profit in FY 2020). Revenue missed analyst estimates by 26%. Earnings per share (EPS) were also behind analyst expectations. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. Employee Representative Member of the Supervisory Board Yi Guo Li is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥4.30, the stock trades at a trailing P/E ratio of 50x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Negligible returns to shareholders over past three years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.056 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥748.9m (up 29% from 3Q 2020). Net income: CN¥53.2m (down 54% from 3Q 2020). Profit margin: 7.1% (down from 20% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥0.024 (vs CN¥0.021 in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: CN¥448.6m (down 41% from 2Q 2020). Net income: CN¥50.3m (up 18% from 2Q 2020). Profit margin: 11% (up from 5.6% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • Jun 03
Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09, June 2021 Hunan Er-Kang Pharmaceutical Co. Ltd. announced 2020 final profit distribution plan to be implemented (A shares). Cash dividend/10 shares CNY 0.50000000 (tax included). Record date is 08, June 2021, Ex-date is 09, June 2021, Payment date is 09, June 2021. Announcement • May 22
Hunan Er-Kang Pharmaceutical Co., Ltd Approves Final Cash Dividend for the Year 2020 Hunan Er-Kang Pharmaceutical Co. Ltd. announced at the AGM held on 20, 2021 that the company approved final cash dividend of CNY 0.50000000 per 10 shares (tax included) for the year 2020. Reported Earnings • Apr 30
First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.012 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥383.8m (down 13% from 1Q 2020). Net income: CN¥53.0m (up 124% from 1Q 2020). Profit margin: 14% (up from 5.4% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • Apr 29
Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2020 Hunan Er-Kang Pharmaceutical Co. Ltd. proposed final cash dividend of CNY 0.50000000 per 10 shares (tax included) for the year 2020. Is New 90 Day High Low • Jan 29
New 90-day low: CN¥3.79 The company is down 25% from its price of CN¥5.04 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Dec 30
New 90-day low: CN¥4.17 The company is down 22% from its price of CN¥5.38 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Dec 10
New 90-day low: CN¥4.57 The company is down 10.0% from its price of CN¥5.10 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. Reported Earnings • Oct 14
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥177.9m, up 110% from the prior year. Total revenue was CN¥2.58b over the last 12 months, down 6.6% from the prior year. Announcement • Aug 13
Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020 Hunan Er-Kang Pharmaceutical Co., Ltd announced that they will report first half, 2020 results on Aug 28, 2020